Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis

Código QR

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis

Martin Hýža,1,2 Petr &Scaron;ilhán,1,2 Eva Če&scaron;ková,1,2 Tomá&scaron; Skřont,1 Ivana Kacířová,3,4 Romana Uřinovská,3 Milan Grundmann4 1Department of Psychiatry, University Hospital Ostrava, Ostrava, Czech R...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hýža M, Šilhán P, Češková E, Skřont T, Kacířová I, Uřinovská R, Grundmann M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	therapeutic drug monitoring antipsychotics psychotic disorders schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/0a94387aecc344cfb5efa8be06bfe03b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
por: Sajatovic M, et al.
Publicado: (2018)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic M, et al.
Publicado: (2018)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)

Clinical schizophrenia & related psychoses
Publicado: (2007)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo I, et al.
Publicado: (2018)

Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
por: Bracha Erlanger Avigdor, et al.
Publicado: (2021)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini F, et al.
Publicado: (2019)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
por: Ohnishi T, et al.
Publicado: (2021)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021)

Revisiting the Concepts of Secondary Schizophrenia and Pseudoschizophrenia
por: João Gama Marques
Publicado: (2021)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Stephan Hjorth, et al.
Publicado: (2021)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Ping Yin, et al.
Publicado: (2021)

Investigaciones en rehabilitación cognitiva para pacientes con esquizofrenia (2004-2013): una revisión temática en beneficio de propuestas para etapas iniciales del trastorno
por: Loubat O,Margarita, et al.
Publicado: (2014)

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study
por: Patrick Köck, et al.
Publicado: (2021)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
por: Chiu LL, et al.
Publicado: (2019)

Comparative Study of the Effects of Atypical Antipsychotic Drugs on Plasma and Urine Biomarkers of Oxidative Stress in Schizophrenic Patients
por: Dietrich-Muszalska A, et al.
Publicado: (2021)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis A, et al.
Publicado: (2016)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
por: Suda A, et al.
Publicado: (2018)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
por: Tzu-Pei Yeh, et al.
Publicado: (2021)

Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
por: Xu H, et al.
Publicado: (2019)

Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile
por: Zolezzi M, et al.
Publicado: (2021)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso C, et al.
Publicado: (2017)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir S, et al.
Publicado: (2016)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga S, et al.
Publicado: (2021)

Diagnóstico clínico y psicométrico de la depresión en pacientes de medicina general
por: Ruiz T,Aída, et al.
Publicado: (2001)

Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications
por: Lei Chen, et al.
Publicado: (2021)

Discrepancy in Taiwanese psychiatrists’ preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey
por: Liu CH, et al.
Publicado: (2018)

Use of atypical antipsychotics in the elderly: a clinical review
por: Gareri P, et al.
Publicado: (2014)

Psychosis
Publicado: (2009)

Esquizofrenia y su asociación con enfermedades médicas crónicas
por: Orellana,Gricel, et al.
Publicado: (2017)

Coping strategies and quality of life in schizophrenia: cross-sectional study
por: Holubova M, et al.
Publicado: (2015)

Drug Attitude, Insight, and Patient’s Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey
por: Nagai N, et al.
Publicado: (2020)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang X, et al.
Publicado: (2019)

A systematic review of the effects of psychiatric medications on social cognition
por: Zoë Haime, et al.
Publicado: (2021)

Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study
por: Huang YC, et al.
Publicado: (2018)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi T, et al.
Publicado: (2017)